Vlp immunotherapy combined with ablation
AssigneeThe Regents of the University of California
InventorsNicole F. Steinmetz, Isabel Newton, Nicholas Webster, Tyler Mandt, Hui Cai, Christine Boone, Mansur Ghani
Life of this patent
Estimating the term…
Abstract
Provided herein is a novel, multimodal in situ vaccination approach to treat cancer by combining ablation with administration of the naturally occurring plant virus or virus-like particle (VLP) nanoparticles such as cowpea mosaic virus (CPMV), a plant virus-based immunoadjuvant.
Claims27
A method of one or more of:
- treating or inhibiting the growth of a tumor or cancer in a subject in need thereof comprising administration of an effective amount of a naturally occurring plant virus or an engineered virus like particle (“VLP”) and subsequent ablation of the tumor or cancer, optionally wherein the cancer is localized or metastatic and optionally wherein the naturally occurring plant virus or the engineered VLP is administered in a composition, optionally wherein the administration is systemic or local to the tumor or cancer in the subject, and optionally wherein the ablation of the tumor or cancer comprises a method selected from one or more of cryoablation, irreversible electroporation, radiofrequency ablation, or microwave ablation.
2-3. (Canceled)
(canceled)
11-12. (canceled)
(canceled)
A composition comprising a naturally occurring plant virus or engineered virus like particle (“VLP”) wherein the naturally occurring plant virus or VLP further comprises a toll-like receptor (“TLR”) agonist, optionally a TLR 2, 3, 4, 7 and/or 9 agonist, and optionally a carrier, and further optionally a detectable label, optionally wherein the TLR agonist is packaged within the naturally occurring plant virus or the engineered VLP.
(canceled)
(canceled)
27-28. (canceled)
Dependencies are inferred from the claim text.